X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (22) 22
aged (18) 18
male (18) 18
oncology (18) 18
female (17) 17
middle aged (16) 16
cancer (11) 11
index medicus (11) 11
adult (10) 10
chemotherapy (10) 10
treatment outcome (9) 9
aged, 80 and over (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
care and treatment (7) 7
carcinoma, non-small-cell lung - drug therapy (6) 6
lung neoplasms - drug therapy (6) 6
research (6) 6
carcinoma, non-small-cell lung - pathology (5) 5
lung cancer (5) 5
lung neoplasms - pathology (5) 5
trial (5) 5
tumors (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
cisplatin (4) 4
cisplatin - administration & dosage (4) 4
clinical trials (4) 4
combination (4) 4
gastroenterology & hepatology (4) 4
italy (4) 4
medicine & public health (4) 4
prospective studies (4) 4
radiotherapy (4) 4
retrospective studies (4) 4
survival (4) 4
time factors (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
comparative analysis (3) 3
disease-free survival (3) 3
dosage and administration (3) 3
drug administration schedule (3) 3
follow-up studies (3) 3
gastroenterology and hepatology (3) 3
gefitinib (3) 3
gemcitabine (3) 3
guanine - analogs & derivatives (3) 3
lung cancer, non-small cell (3) 3
lung neoplasms - mortality (3) 3
management (3) 3
mesothelioma - drug therapy (3) 3
mesothelioma - pathology (3) 3
neutropenia - chemically induced (3) 3
non-small cell lung cancer (3) 3
non-small-cell lung cancer (3) 3
oncology, experimental (3) 3
pancreatitis (3) 3
pancreatitis - etiology (3) 3
pancreatitis - surgery (3) 3
pemetrexed (3) 3
pharmacology & pharmacy (3) 3
pharmacology/toxicology (3) 3
pleural neoplasms - drug therapy (3) 3
pleural neoplasms - pathology (3) 3
quality-of-life (3) 3
radiation-therapy (3) 3
randomized-trial (3) 3
severity of illness index (3) 3
squamous-cell carcinoma (3) 3
surgery (3) 3
toxicity (3) 3
vinblastine - administration & dosage (3) 3
vinblastine - analogs & derivatives (3) 3
abridged index medicus (2) 2
acute disease (2) 2
anti-bacterial agents - therapeutic use (2) 2
antineoplastic agents - therapeutic use (2) 2
breast-cancer (2) 2
cancer survivors (2) 2
cancer survivorship (2) 2
carboplatin (2) 2
carcinoma, non-small-cell lung - mortality (2) 2
carcinoma, squamous cell - drug therapy (2) 2
carcinoma, squamous cell - pathology (2) 2
cholangiopancreatography, endoscopic retrograde (2) 2
clinical outcomes (2) 2
combined modality therapy (2) 2
deoxycytidine - administration & dosage (2) 2
deoxycytidine - analogs & derivatives (2) 2
diagnosis (2) 2
doxorubicin (2) 2
drug dosages (2) 2
egfr (2) 2
erlotinib (2) 2
esophageal neoplasms - drug therapy (2) 2
esophageal neoplasms - pathology (2) 2
esophageal neoplasms - radiotherapy (2) 2
european-organization (2) 2
gabexate mesilate (2) 2
glutamates - administration & dosage (2) 2
guanine - administration & dosage (2) 2
guidelines (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American journal of respiratory and critical care medicine, ISSN 1073-449X, 05/2015, Volume 191, Issue 10, pp. 1166 - 1175
Journal Article
American Journal of Clinical Oncology: Cancer Clinical Trials, ISSN 0277-3732, 2018, Volume 41, Issue 3, pp. 280 - 285
Journal Article
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, ISSN 0277-3732, 03/2018, Volume 41, Issue 3, pp. 280 - 285
Aims:To compare the surgical and survival outcomes of patients undergoing primary debulking surgery (PDS) versus neoadjuvant chemotherapy (NACT) plus interval... 
NACT | SURVIVAL | CYTOREDUCTIVE SURGERY | ovarian cancer | residual disease | RISK | TIME | interval debulking surgery | IV OVARIAN | ONCOLOGY | ADVANCED-STAGE OVARIAN | CARCINOMA | PDS | Neoadjuvant therapy | Care and treatment | Comparative analysis | Patient outcomes | Ovarian cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2016, Volume 34, Issue 3_suppl, pp. e275 - e275
e275 Background: The population of cancer-survivors faces different lifetime health risk. Thus, models for high-quality and personalized care delivery are... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 5_suppl, pp. 40 - 40
40 Background: In our Institution, we started a survivorship care program that integrates survivors’ health care provided by the oncologist and the primary... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2018, Volume 36, Issue 7_suppl, pp. 170 - 170
170 Background: While there are different studies investigating the quality of life (QoL) of cancer patients (pts) during active treatment, few studies report... 
Journal Article
Journal Article
Journal Article
The Oncologist, ISSN 1083-7159, 10/2018, Volume 23, Issue 10, pp. 1133 - e112
Lessons Learned NGR‐hTNF was safely combined with doxorubicin, showing a promising antitumor activity in unselected patients with relapsed small cell lung... 
TRIAL | TUMOR-NECROSIS-FACTOR | ONCOLOGY | PHASE IB | VASCULATURE | TOPOTECAN | TNF | IPILIMUMAB | FACTOR-ALPHA | INFILTRATION | DELIVERY | Index Medicus | Clinical Trial Results
Journal Article
by Cardinale, D and Cardinale, Daniela and Ciceri, Fabio and Ciceri, F and Latini, R and Latini, Roberto and Franzosi, Maria Grazia and Franzosi, M.G and Sandri, Maria Teresa and Sandri, M.T and Civelli, M and Civelli, Maurizio and Cucchi, GianFranco and Cucchi, G and Menatti, E and Menatti, Elisabetta and Mangiavacchi, M and Mangiavacchi, Maurizio and Cavina, R and Cavina, Raffaele and Barbieri, Enrico and Barbieri, E and Gori, S and Gori, Stefania and Colombo, Alessandro and Colombo, A and Curigliano, Giuseppe and Salvatici, M and Salvatici, Michela and Rizzo, A and Rizzo, Antonio and Ghisoni, Francesco and Ghisoni, F and Bianchi, A and Bianchi, Alessandra and Falci, Cristina and Falci, C and Aquilina, M and Aquilina, Michele and Rocca, A and Rocca, Andrea and Monopoli, A and Monopoli, Anna and Milandri, Carlo and Milandri, C and Rossetti, Giuseppe and Bregni, M and Bregni, Marco and Sicuro, Marco and Sicuro, M and Malossi, Alessandra and Malossi, A and Nassiacos, Daniele and Nassiacos, D and Verusio, C and Verusio, Claudio and Giordano, M and Giordano, Monica and Staszewsky, Lidia and Staszewsky, L and Barlera, S and Barlera, Simona and Nicolis, E and Nicolis, Enrico B and Magnoli, Michela and Magnoli, M and Masson, S and Masson, Serge and Cipolla, Carlo M and Cipolla, C.M and Maggioni, A.P and Labianca, R and Tettamanti, M and Senni, M and Finzi, A and Grosso, F and Vago, T and Gramenzi, S and Balconi, G and Bernasconi, R and Buratti, M.G and Ojeda Fernandez, M.L and Vasamì, A and Thiebat, B and Barè, C and Corzani, A and Coccolo, F and Colecchia, S and Pellegrini, C and Appio, L and Caico, I and G.Rossetti and Mesenzani, O and Campana, C and Gilardoni, M and Scognamiglio, G and Corrado, G and Battagin, D and De Rosa, F and Carpino, C and ... and ICOS-ONE Study Investigators
European Journal of Cancer, ISSN 0959-8049, 05/2018, Volume 94, pp. 126 - 137
Journal Article
Cancer, ISSN 0008-543X, 04/2008, Volume 112, Issue 7, pp. 1555 - 1561
BACKGROUND Pemetrexed‐cisplatin chemotherapy is the standard of care in the first‐line treatment of unresectable malignant pleural mesothelioma (MPM).... 
malignant pleural mesothelioma | gemcitabine‐vinorelbine combination | second‐line chemotherapy | pemetrexed‐pretreated patients | Second-line chemotherapy | Gemcitabine-vinorelbine combination | Malignant pleural mesothelioma | Pemetrexed-pretreated patients | gemcitabine-vinorelbine combination | CARBOPLATIN | MANAGEMENT | second-line chemotherapy | OXALIPLATIN | COMBINATION | CANCER | CHEMOTHERAPY | PHASE-II TRIAL | CISPLATIN | ONCOLOGY | END-POINT | 2ND-LINE TREATMENT | pemetrexed-pretreated patients | Prospective Studies | Follow-Up Studies | Mesothelioma - pathology | Guanine - analogs & derivatives | Humans | Middle Aged | Male | Mesothelioma - mortality | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Pleural Neoplasms - drug therapy | Vinblastine - analogs & derivatives | Aged, 80 and over | Female | Chemotherapy, Adjuvant | Pleural Neoplasms - pathology | Deoxycytidine - administration & dosage | Survival Rate | Treatment Outcome | Pleural Neoplasms - mortality | Pemetrexed | Mesothelioma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Glutamates - administration & dosage | Aged | Deoxycytidine - analogs & derivatives | Guanine - administration & dosage | Mesothelioma | Care and treatment | Chemotherapy, Combination | Dosage and administration | Research | Gemcitabine | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 5/2009, Volume 63, Issue 6, pp. 1111 - 1119
The aim of this study was to evaluate the activity and safety of oxaliplatin/5-fluorouracil-based chemo-radiotherapy in patients with not radically resectable... 
Phase II study | Biomedicine | Oxaliplatin | Cancer Research | Oncology | Chemo-radiotherapy | Pharmacology/Toxicology | Esophageal cancer | HISTOLOGIC TUMOR TYPE | 10-YEAR PROSPECTIVE COHORT | 1,000 CONSECUTIVE RESECTIONS | RANDOMIZED-TRIAL | INFUSION FLUOROURACIL | GASTRIC CARDIA | PATHOLOGICAL COMPLETE RESPONSE | RECTAL-CANCER | ONCOLOGY | INDEPENDENT PROGNOSTIC PARAMETER | SQUAMOUS-CELL CARCINOMA | PHARMACOLOGY & PHARMACY | Leucovorin - administration & dosage | Adenocarcinoma - pathology | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Squamous Cell - surgery | Male | Esophageal Neoplasms - radiotherapy | Carcinoma, Squamous Cell - radiotherapy | Esophageal Neoplasms - pathology | Fluorouracil - therapeutic use | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Esophageal Neoplasms - surgery | Adult | Female | Leucovorin - therapeutic use | Adenocarcinoma - radiotherapy | Drug Administration Schedule | Neoplasm Invasiveness | Kaplan-Meier Estimate | Esophagectomy | Combined Modality Therapy | Radiation Dosage | Adenocarcinoma - drug therapy | Disease-Free Survival | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Esophageal Neoplasms - drug therapy | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Adenocarcinoma - surgery | Care and treatment | Oncology, Experimental | Radiation | Diarrhea | Clinical trials | Leucovorin | Product development | Research | Radiotherapy | Fluorouracil | Cancer | Index Medicus
Journal Article
Journal Article